Position in NVO
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$4,794,000
+$4,258,296 QoQ
Shares Held
100,000
+586.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
1.81%
of 13F equity value
Holder Rank
#227
of 1,348 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Derivatives in NVO
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$2,679,846
PutShares
55,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $10,595,985 across 3 Drug Manufacturers - General names. NVO ranks #2 (45.2% of the industry book) .
All Filings in NVO
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,679,846 | 55,900 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $4,794,000 | 100,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $535,704 | 14,577 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $2,054,325 | 55,900 | Put | Sole | 2026-05-15 | |
| 2025-12-31 | $2,701,728 | 53,100 | Put | Sole | 2026-02-17 | |
| 2025-09-30 | $5,549,000 | 100,000 | Put | Sole | 2025-11-14 | |
| 2025-09-30 | $1,387,250 | 25,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $6,902,000 | 100,000 | Call | Sole | 2025-08-14 | |
| 2025-03-31 | $1,709,473 | 24,618 | Shares | Sole | 2025-05-15 | |
| 2025-03-31 | $8,652,224 | 124,600 | Put | Sole | 2025-05-15 | |
| 2025-03-31 | $7,548,128 | 108,700 | Call | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||